At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MANE Veradermics, Inc.
Not Yet Opened 05-13 16:00:00 EDT
107.14
+3.24
+3.12%
盘后107.14
+0.000.00%
19:58 EDT
High110.13Low102.70Vol341.84K
Open104.00D1 Closing103.90Amplitude7.15%
Mkt Cap4.41BTradable Cap1.87BTotal Shares41.18M
T/O36.74MT/O Rate1.96%Tradable Shares17.46M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Veradermics Faces Financing Risk as Cashless Pre-Funded Warrants Offer Little to No Capital Infusion
TIPRANKS  ·  14:01
Veradermics Faces Financing Risk as Cashless Pre-Funded Warrants Offer Little to No Capital Infusion
Veradermics Q1 Net Loss Widens
MT Newswires Live  ·  05-12 20:05
Veradermics Q1 Net Loss Widens
Veradermics reports Q1 net income ($27.2M) vs ($12.4M) last year
TIPRANKS  ·  05-12 19:57
Veradermics reports Q1 net income ($27.2M) vs ($12.4M) last year
Veradermics releases corporate deck outlining VDPHL01 oral minoxidil program for pattern hair loss
Reuters  ·  05-12 19:37
Veradermics releases corporate deck outlining VDPHL01 oral minoxidil program for pattern hair loss
Earnings Flash (MANE) Veradermics Posts Q1 Net Loss $27.2M, vs. FactSet Est of $22.9M Loss
MT Newswires Live  ·  05-12 19:35
Earnings Flash (MANE) Veradermics Posts Q1 Net Loss $27.2M, vs. FactSet Est of $22.9M Loss
Veradermics Q1 FY26 net loss widens to $27.2 million; R&D expenses rise to $20.9 million
Reuters  ·  05-12 19:30
Veradermics Q1 FY26 net loss widens to $27.2 million; R&D expenses rise to $20.9 million
Veradermics Inc - Cash, Cash Equivalents and Marketable Securities Total $390.8 Mln as of March 31, 2026
THOMSON REUTERS  ·  05-12 19:30
Veradermics Inc - Cash, Cash Equivalents and Marketable Securities Total $390.8 Mln as of March 31, 2026
Press Release: Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Dow Jones  ·  05-12 19:30
Press Release: Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics files initial beneficial ownership statement by Seven Fleet Capital Management LP
Reuters  ·  05-06
Veradermics files initial beneficial ownership statement by Seven Fleet Capital Management LP
Veradermics Boosts Capital Through Public Offering and Warrants
TIPRANKS  ·  05-02
Veradermics Boosts Capital Through Public Offering and Warrants
Looking to Regrow Hair? New Options Are on the Horizon -- WSJ
Dow Jones  ·  05-01
Looking to Regrow Hair? New Options Are on the Horizon -- WSJ
Is It Too Late To Consider Veradermics (MANE) After A 162% Year To Date Surge?
Simply Wall St.  ·  05-01
Is It Too Late To Consider Veradermics (MANE) After A 162% Year To Date Surge?
BUZZ-U.S. STOCKS ON THE MOVE-Quanta, O'Reilly Automotive, Avis
Reuters  ·  05-01
BUZZ-U.S. STOCKS ON THE MOVE-Quanta, O'Reilly Automotive, Avis
BUZZ-Veradermics climbs, then eases after upsized $414 mln equity offering
Reuters  ·  04-30
BUZZ-Veradermics climbs, then eases after upsized $414 mln equity offering
Veradermics Prices Upsized Public Offering, Enters Private Placement
MT Newswires Live  ·  04-30
Veradermics Prices Upsized Public Offering, Enters Private Placement
Veradermics 3.84M share Secondary priced at $100.00
TIPRANKS  ·  04-30
Veradermics 3.84M share Secondary priced at $100.00
BRIEF-Veradermics Announces Pricing Of Upsized Public Offering And Private Placement
Reuters  ·  04-30
BRIEF-Veradermics Announces Pricing Of Upsized Public Offering And Private Placement
Veradermics prices $30 million private placement of pre-funded warrants with Suvretta Capital affiliates
Reuters  ·  04-30
Veradermics prices $30 million private placement of pre-funded warrants with Suvretta Capital affiliates
Veradermics Inc - Announces Upsized Public Offering of 3,843,790 Shares at $100.00 per Share
THOMSON REUTERS  ·  04-30
Veradermics Inc - Announces Upsized Public Offering of 3,843,790 Shares at $100.00 per Share
Veradermics Hair Loss Trial Success Spurs Funding Plans For VDPHL01
Simply Wall St.  ·  04-29
Veradermics Hair Loss Trial Success Spurs Funding Plans For VDPHL01

Introduction

Company Name.
Veradermics, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Issue price:
--